CEBPA Mutation Detection Test in UAE | 1500 AED | DHA Licensed Genomics

Executive Summary & Core Metrics

The CEBPA Mutation Detection Test is a high-precision molecular genomic assay designed to identify pathogenic mutations within the CCAAT/Enhancer-Binding Protein Alpha (CEBPA) gene, which are strongly associated with Acute Myeloid Leukemia (AML) prognosis and risk stratification. This PCR-based analysis empowers oncologists and hematologists across the UAE with actionable genomic intelligence, enabling personalized therapeutic decision-making aligned with current DHA Clinical Genomic Guidelines. Priced at 1,500 AED inclusive of certified laboratory processing and optional VIP mobile phlebotomy, the test delivers a definitive molecular result within 10 working days via an ISO 9001:2015 accredited workflow.

✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM daily).
✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance for comprehensive result interpretation by DHA-licensed genetics specialists.
✓ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The CEBPA Mutation Detection Test utilizes targeted PCR amplification followed by bidirectional Sanger sequencing confirmation and allele-specific amplification to detect both biallelic and monoallelic mutations in the CEBPA gene. This focused approach delivers superior single-gene depth compared to broad NGS panels, ensuring comprehensive coverage of all coding exons and intronic regulatory regions critical for accurate AML risk classification per European LeukemiaNet (ELN) 2026 guidelines. The assay is validated for whole blood specimens collected in Lavender Top EDTA tubes and maintained under strict refrigerated cold-chain conditions (2–8°C) to preserve DNA integrity throughout the 10-working-day analytical workflow.

Feature	Our CEBPA Test (DHA Certified)	Closest Alternative (Standard NGS Panel)
Precision / Methodology	Targeted PCR with Bidirectional Sanger Sequencing Confirmation; Allele-Specific Amplification	Broad Next-Generation Sequencing (NGS); Lower Single-Gene Depth
Turnaround Time	10 Working Days (Expedited Reporting Available)	14–21 Working Days
Clinical Applicability	Focused CEBPA Biallelic & Monoallelic Mutation Analysis per ELN 2026 AML Risk Classification	Incidental CEBPA Coverage; May Miss Intronic Regulatory Region Variants
Sample Stability	ISO Cold-Chain Refrigerated Transport (2–8°C); Strict Freeze Prohibition Protocol	Variable; Ambient Transport May Compromise DNA Integrity
Price (AED)	1500 AED — All-Inclusive	1800–2500 AED (Variable; Excludes Phlebotomy)

Physician Insight & Safety Protocols

Clinical Note from Lina Osama Zaki Quteineh — Consultant Medical Genetics, DHA Registration ID: 9294403:

"A CEBPA mutation result — whether biallelic or monoallelic — must always be interpreted within the full clinical and cytogenetic context of the patient. I emphasize that a favorable-risk biallelic CEBPA mutation does not eliminate the need for vigilant post-remission surveillance, and all findings should be correlated with bone marrow morphology, flow cytometry, and NPM1/FLT3-ITD co-mutational status. This test provides a critical molecular compass, but it is your comprehensive clinical assessment that truly navigates the treatment journey."

Critical Medication Advisory

⚠ Critical Medication Notice

Do not discontinue, adjust, or initiate any prescribed medication, including targeted therapy, chemotherapy, or supportive care agents, without consulting your treating oncologist or hematologist. Genetic test results are one component of multidisciplinary clinical decision-making and must never independently drive therapeutic changes.

Exclusion Criteria & Emergency Red Flags

Exclusion Criteria (Do Not Proceed with Routine Collection):

Patient has undergone allogeneic stem cell transplantation within the last 90 days (donor DNA contamination risk).
Active uncontrolled bleeding or platelets below 10,000/µL without physician clearance for venipuncture.
Incomplete or missing Genomics Clinical Information Requisition Form (Form 20) — collection must be deferred.
Sample collected in any tube other than Lavender Top (EDTA); heparin tubes are strictly contraindicated (PCR inhibition).

🚨 ER Red Flags — Seek Immediate Medical Attention:

New-onset fever ≥38.3°C with absolute neutrophil count below 500/µL.
Uncontrolled bleeding, petechial rash, or sudden neurological changes (possible leukostasis or DIC).
Severe dyspnea or hypoxia in a leukemic patient (rule out leukostasis or differentiation syndrome).
Acute abdominal pain or splenic rupture symptoms in a patient with known splenomegaly.

If any red flag symptom is present, proceed directly to the nearest Emergency Department. Do not wait for genetic test results.

Patient FAQ & Clinical Guidance

1. What exactly does the CEBPA Mutation Detection Test diagnose, and why is it essential for leukemia patients?

Snippet Answer: The CEBPA Mutation Detection identifies pathogenic mutations in the CEBPA gene that directly influence Acute Myeloid Leukemia risk classification, prognosis, and treatment planning. Clinicians utilize CEBPA mutational status — particularly biallelic mutations — as a favorable-risk molecular marker per the European LeukemiaNet (ELN) 2026 guidelines, enabling de-escalation of chemotherapy intensity when appropriate and sparing patients from unnecessary stem cell transplantation in first complete remission. This precision approach transforms a generic AML diagnosis into a genomically informed, personalized therapeutic roadmap.

2. How should I prepare for the blood sample collection, and what does the mandatory Form 20 require?

Snippet Answer: Preparation requires completing the Genomics Clinical Information Requisition Form (Form 20) with your referring oncologist, detailing your complete hematological history, prior chemotherapy regimens, and family cancer history. The blood draw itself requires no fasting; however, a 4 mL whole blood sample collected in a Lavender Top EDTA tube, shipped refrigerated at 2–8°C without freezing, is mandatory for accurate PCR-based mutation detection and DNA preservation integrity throughout the 10-working-day analytical workflow.

3. How long does it take to receive the CEBPA mutation result, and is the result accuracy guaranteed?

Snippet Answer: The final CEBPA mutation report is issued within 10 working days following bidirectional sequence confirmation to ensure a diagnostic accuracy of 99.9%. The laboratory is internationally accredited under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139), and all analyses are performed in accordance with DHA clinical genomics protocols. Direct telephonic consultation with the consultant medical geneticist is available for comprehensive clinical interpretation of the result.

UAE Regulatory & Data Privacy Adherence

📚 Data Privacy & Health Information Governance:

All genomic data handling complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient genomic information is encrypted, access-controlled, and processed under strict confidentiality protocols aligned with international best practices for sensitive genetic data.

⚖ Clinical Safety & Medical Liability:

Clinical testing safety, patient consent, and practitioner accountability are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic testing procedures require explicit informed consent and are conducted under the supervision of DHA-licensed medical genetics consultants.

🏅 Authority & Accreditation:

ISO 9001:2015 Certified — Cert: INT/EGQ/2509DA/3139. DHA Facility License: 1143. All methodologies validated per current clinical genomics standards with cross-validation protocols where applicable.

📞 Contact & Support:

WhatsApp: +971 54 548 8731
VIP Mobile Phlebotomy: 8 AM – 11 PM Daily
Email: genomics@dnalabsuae.ae
Reviewed by: Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA 9294403

Clinical & Logistical Metadata

Test Name	CEBPA Mutation Detection Test
Price (AED)	1,500 AED (All-Inclusive)
Turnaround Time	10 Working Days
Sample Type / Matrix	Whole Blood (Lavender Top EDTA Tube) — VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection
Methodology Used	Targeted PCR with Bidirectional Sanger Sequencing Confirmation; Allele-Specific Amplification
ICD-10-CM Code	C92.00 (Acute myeloblastic leukemia, not having achieved remission)
LOINC Code	91770-4 (CEBPA gene mutation analysis in Blood)
DHA Facility License & Laboratory Address	License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE